Human neurocysticercosis managed at Nepalganj Medical College, Teaching Hospital, Kohalpur, Nepal.
BACKGROUND
Neurocysticercosis is the most common parasitic infection of the central nervous system. It is endemic in Central Europe, South Africa, South America and parts of Asia including Nepal.


OBJECTIVE
This study has been conducted with the objectives to know the diagnostic criteria for neurocysticercosis and the outcome of treated cases.


METHODS
This retrospective study was done at Nepalganj Medical College, Teaching Hospital, Kohalpur, by reviewing the record of the patients managed as case of neurocysticercosis in one financial year.


RESULTS
All patients presented with seizure as a main symptom started in adult life. The mean age was 21 years; 80% were male and 20% female. The diagnosis seemed to be based on clinical presentation, CT scan findings and high index of suspicion. All were put on albendazole, steroids and anticonvulsant drugs; 93% was discharged when fits got controlled, one patient left against medical advice. Follow up record was not available to comment on resolution.


CONCLUSIONS
Neurocysticercosis is difficult to diagnose and has a significant socioeconomic impact because of chronic morbidity, variable mortality, decreased productivity of affected persons, and high cost of medical diagnosis and treatment. It is therefore suggested to develop criteria for diagnosis of neurocysticercosis to be followed at national level.
Piryani
R M
RM
Department of Medicine, Nepalganj Medical College, Nepalganj, Nepal. r_piryani@yahoo.com
Kohli
S C
SC
Shrestha
G
G
Shukla
A
A
Malla
T B
TB
D000328:Adult; D015766:Albendazole / Q000627:therapeutic use; D000923:Anticestodal Agents / Q000627:therapeutic use; D000927:Anticonvulsants / Q000627:therapeutic use; D005260:Female; D006784:Hospitals, Teaching; D006801:Humans; D008297:Male; D009390:Nepal / Q000453:epidemiology; D020019:Neurocysticercosis / Q000188:drug therapy* / Q000453:epidemiology; D012189:Retrospective Studies; D013256:Steroids / Q000627:therapeutic use; D016896:Treatment Outcome
D000923:Anticestodal Agents; D000927:Anticonvulsants; D013256:Steroids; D015766:Albendazole